Bristol Myers Squibb and Repertoire Announce $1.8B Deal to Reset Immune System in Autoimmune Patients
Repertoire Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strateg
Last Week's Worst-Performing Stocks: Are These 10 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
With the earnings season in full swing, these ten large-cap stocks were the worst performers last week. Are they in your portfolio?LKQ Corporation (NASDAQ:LKQ) stock tumbled 12.3% after the company re
US Stock Earnings Quarterly Review: Nearly 80% of the results exceeded expectations, and the market is more optimistic
Among the constituent stocks of the S&P 500 index, 229 have already published financial reports. Of these, nearly 80% have performed better than market expectations, which makes the market more optimistic about the profit estimates of US stock companies.
Bristol-Myers Squibb First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Bristol-Myers Squibb Price Target Cut to $48.00/Share From $55.00 by BMO Capital
Bristol-Myers Squibb Price Target Cut to $48.00/Share From $55.00 by BMO Capital
Bank of Montreal, Canada: Maintaining the Bristol-Myers Squibb (BMY.US) rating, adjusted from a consistent market rating to a consistent market rating, and the target price was adjusted from $55.00 to $48.00.
Bank of Montreal, Canada: Maintaining the Bristol-Myers Squibb (BMY.US) rating, adjusted from a consistent market rating to a consistent market rating, and the target price was adjusted from $55.00 to $48.00.
Barclays Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $43
Barclays analyst Carter Gould maintains Bristol-Myers Squibb with a Equal-Weight and lowers the price target from $51 to $43.
Bristol-Myers Squibb Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/26/2024 -3.57% Barclays $51 → $43 Maintains Equal-Weight 04/18/2024 16.62% Wells Fargo $51 → $52 Mainta
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy
Bristol-Myers Squibb (BMY) said Friday that a European regulator has recommended approval of Opdivo in combination with cisplatin and gemcitabine for the first-line treatment of adult patients having
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Bristol Myers Gets CHMP Backing for Opdivo Combo in Bladder Cancer
By Colin Kellaher Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its blockbuster cancer drug Opdiv
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55
Bristol-Myers Squibb Company (BMY) has an average rating of hold and price targets ranging from $37 to $75, according to analysts polled by Capital IQ. Price: 44.93, Change: +0.23, Percent Change: +0.
Bristol Myers Says EMA's CHMP Recommended Approval Of Opdivo Combination With Cisplatin, Gemcitabine For First-line Treatment Of Adult Patients With Unresectable Or Metastatic Urothelial Carcinoma
The European Commission (EC), which has the authority to approve medicines for the European Union (EU), will now review the CHMP recommendation. The final EC decision is expected in June 2024.
This week's US bullish stocks | Performance and stock prices go hand in hand! Nvidia's exclusive liquid cooling supplier Vertiv surged more than 20% during the week
It was announced that it would accelerate the launch of cheap models, and Tesla had a cumulative increase of 15.73% during the week; database giant MongoDB surged nearly 12%, reaching 465 US dollars.
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Laboratory (LH) and Bristol-Myers Squibb (BMY)
Analysts fell to the sidelines weighing in on Universal Health (UHS), Laboratory (LH) and Bristol-Myers Squibb (BMY) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Bristol-Myers Squibb: Hold Rating Amid Mixed Performance and Future Revenue Concerns
Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Bristol-Myers Squibb (BMY), retaining the price target of $52.00.
Barclays Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
Barclays analyst Carter Gould maintained a Hold rating on Bristol-Myers Squibb (BMY) today and set a price target of $43.00.
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
The CNN Money Fear and Greed index showed a slight improvement in the overall market sentiment, while the index remained in the "Fear" zone on Thursday.U.S. stocks settled lower on Thursday, following
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
Health Care Drops Amid Mixed Earnings -- Health Care Roundup
Health-care companies fell after mixed earnings. Bristol-Myers Squibb shares tumbled after the drug giant said it would lay off roughly 2,200 people in an effort to compensate for a slowdown in the s
No Data